Tag

Copd

All articles tagged with #copd

health7 days ago•18 min saved

Texas COPD Patient's Suicide Highlights Insurance Navigation Failures

Kenney Blewett, a Texas man with chronic obstructive pulmonary disease, died by suicide in June 2026 after a prescribed medication was delayed due to insurance confusion. His wife, Cindy, attributes his death to the stress of worsening health and the failure of the healthcare system to deliver treatment. The delay stemmed from conflicting records between Medicare Part B and Part D, as well as missing diagnostic codes. This case highlights the ongoing risks of prior authorization and complex insurance navigation for elderly patients.

via The Independent|

#copd #health #insurance-delays

health7 days ago•6 min saved

Texas COPD Patient Dies by Suicide After Insurance Confusion Delays Critical Medication

Kenney Blewett, a Texas man with chronic obstructive pulmonary disease (COPD), died by suicide in June 2026 after a prescribed medication was delayed due to insurance confusion. His wife, Cindy, attributes his death to the stress of worsening health and the failure of the healthcare system to deliver treatment. The delay stemmed from conflicting records between Medicare Part B and Part D, as well as missing diagnostic codes. This case highlights the ongoing risks of prior authorization and complex insurance navigation for elderly patients.

via KFF Health News|

#copd #health #health-insurance

health8 days ago•6 min saved

Medicare Complexity and Insurance Delays Linked to Fatal Suicide of COPD Patient in Texas

Kenney Blewett, a Texas man with chronic obstructive pulmonary disease (COPD), died by suicide in June 2026 after a critical medication was delayed due to insurance confusion. His wife, Cindy, attributes his death to the stress of worsening health and the failure of the healthcare system to deliver prescribed treatment. The delay stemmed from conflicting records between Medicare Part B and Part D, as well as missing diagnostic codes. This case highlights the ongoing risks of prior authorization and complex insurance navigation for elderly patients.

via CBS News|

#copd #health #health-insurance

health1 month ago•2 min saved

GLP-1 Drugs Linked to Fewer Asthma Attacks in Real-World Data

A UK real-world study finds GLP-1 receptor agonists such as semaglutide (Ozempic) linked to fewer asthma and COPD flare-ups versus sulfonylureas, with about a 40% drop in asthma attacks and a 20% drop in COPD flare-ups, but the findings are observational, not peer‑reviewed, and require clinical trials to establish causation.

via Gizmodo|

#asthma #copd #glp-1

health1 month ago•5 min saved

AZ's tozorakimab shows broad COPD benefits ahead of FDA priority review

AZ’s IL-33 inhibitor tozorakimab delivered meaningful reductions in COPD exacerbations in two pivotal trials (Oberon and Titania), cutting moderate/severe attacks by about 29–34% in former smokers and around 30% overall in current/former smokers. Benefits extended across eosinophil subgroups and included a mucus plug score reduction, suggesting broad, differentiated efficacy. The company has secured FDA priority review, positioning tozorakimab as a potential flagship COPD biologic as it competes with other pipeline therapies.

via fiercebiotech.com|

#astrazeneca #copd #fda-priority-review

health1 month ago•4 min saved

Laugh Therapy May Ease COPD Breathing in a Low-Cost Trial

A Turkish randomized study with 63 COPD patients found that laughter therapy, delivered as playful exercises and laughter routines for 30 minutes three times a week over eight weeks, improves breathing and overall health—comparable to pursed-lip breathing—with benefits lasting about a month after the program, suggesting a low-cost, home-friendly adjunct to COPD care.

via New York Post|

#copd #health #laughter-therapy

healthcare1 month ago•5 min saved

AstraZeneca's tozorakimab posts big COPD trial gains, eyeing multi-billion-dollar sales

AstraZeneca reported positive Phase 3 results for its COPD therapy tozorakimab, showing reductions in moderate and severe flare-ups across broad patient groups, including current and former smokers and across a range of eosinophil counts, with up to 43% reductions in some subsets. The IL-33–targeting antibody is under FDA priority review with potential approval in early 2027, and AZ has lifted its peak sales forecast above $5 billion as it eyes a larger COPD biologics market beyond current options like Dupixent and Nucala.

via CNBC|

#astrazeneca #biologics #copd

science2 months ago•106 min saved

Lung-resident immune cells reveal hidden genetic drivers of autoimmune and lung diseases

A large single-cell eQTL study across 29 lung immune cell subsets from 120 individuals links disease-risk variants to gene expression in tissue-resident immune cells, revealing cell-type–specific regulatory mechanisms for autoimmune diseases and COPD. The researchers identify thousands of eGenes, with hundreds showing colocalization to GWAS signals; COPD heritability is estimated at 15–20% mediated by lung-immune-cell expression, and genes like IRF5, IFITM3, and ZNF683 illustrate how regulatory variants shape immune responses in the lung. Many signals are not detected in blood-based eQTL datasets, highlighting the value of studying tissue-resident cells.

via nature.com|

#copd #eqtl #lung

technology2 months ago•11 min saved

AI-powered remote care slashes COPD and asthma hospitalizations

Intermountain Health and CareCentra’s iCARE program monitored about 1,200 COPD and adult asthma patients across five Utah hospitals over two years using an AI-enabled platform fed by spirometers, pulse oximeters, connected inhaler devices, and wearables. The system detects early deterioration, nudges patients, and escalates to pulmonary navigators, cutting hospitalizations by 50%, emergency visits by 20%, and total care costs by 57% while increasing navigator capacity from roughly 30 to about 220 patients. Results were shared at the ATS 2026 conference, with plans to scale the technology across 34 hospitals.

via KSL.com|

#ai #asthma #copd

health3 months ago•37 min saved

Leafy Greens Linked to Lower COPD Risk via Vitamin K1

A large Australian study from Edith Cowan University, published in The American Journal of Clinical Nutrition, found that higher dietary vitamin K1 from leafy greens (e.g., spinach and kale) is linked to a lower risk of chronic obstructive pulmonary disease (COPD). Over 179,000 adults were followed for a decade, and those with the highest K1 intake were about 16% less likely to develop COPD and showed stronger lung function. The researchers suggest vitamin K1 helps protect lung elastic fibers, while vitamin K2 did not reduce COPD risk. Smoking remains the major COPD risk factor, with diet possibly counteracting some damage but not replacing quitting and pollution reduction.

via CTV News|

#copd #health #leafy-greens

health3 months ago•5 min saved

Leafy greens linked to lower COPD risk, new study suggests

In a large observational study of 179,062 people over about 10.5 years, higher vitamin K1 intake—mainly from leafy greens like spinach and kale—was associated with better lung function and a 16% lower COPD risk, with stronger effects among smokers and those in high-risk occupations; vitamin K2 showed no link. While not proving causation, researchers say increasing leafy greens could be a practical way to boost lung health by raising vitamin K1 intake.

via Fox News|

#copd #diet-and-nutrition #health

healthcare6 months ago•2 min saved

AZ's tozorakimab delivers COPD benefit across populations in Phase 3

AstraZeneca's anti-IL-33 antibody tozorakimab posted positive Phase 3 results in COPD (Oberon and Titania), reducing the annualized rate of moderate-to-severe exacerbations versus placebo in former smokers and showing benefit across the overall population, with a favorable safety profile. The drug’s supposed differentiation comes from complete inhibition of ST2 and RAGE/EGFR signaling, unlike rivals Roche and Sanofi/Regeneron’s IL-33 blockers that produced mixed results. AZ plans to present full data at an upcoming meeting and is pursuing two additional Phase 3 trials (Prospero, Miranda), while maintaining a target of potentially $3–5 billion in peak sales if approved.

via Fierce Biotech|

#astrazeneca #copd #healthcare

health7 months ago•55 min saved

COPD relief hinges on one step: quitting smoking, says GP

GP Dr Philippa Kaye explains COPD is a chronic, incurable lung condition often linked to smoking; while not curable, symptoms can be markedly improved by quitting smoking (the single most important step), engaging in supervised exercise via a pulmonary rehabilitation program, using inhalers correctly, maintaining a healthy weight, and staying up to date with vaccines (flu, pneumococcal, RSV). Seek GP help if breathlessness or coughing worsens.

via Daily Mail|

#copd #health #inhalers

entertainment8 months ago•5 min saved

Chuck Negron, Frontman Behind Three Dog Night's Classic Hits, Dies at 83

Chuck Negron, founding lead singer of Three Dog Night behind hits like 'Joy to the World' and 'One,' died at 83 in Studio City from complications of heart failure and COPD; once plagued by drug issues, he sobered in 1991 and later reconciled with bandmates. He is survived by his wife Ami Albea Negron and five children, including Berry Oakley Jr.

via Fox News|

#chuck-negron #copd #entertainment

obituaries8 months ago•17 min saved

Chuck Negron, Frontman of Three Dog Night, Dies at 83

Chuck Negron, founding member and lead vocalist of the LA rock band Three Dog Night, died at 83 in Studio City after battling COPD and heart failure. Born Charles Negron II in 1942 in the Bronx, he helped form Three Dog Night in 1967 with Danny Hutton and Cory Wells, delivering hits like Joy To The World and One. The group underwent lineup changes amid internal tensions and Negron’s struggles with addiction, though he later pursued a solo career and wrote an autobiography; he and Hutton reportedly reconciled last year. He is survived by his wife Ami Albea Negron and several children and relatives.

via Deadline|

#chuck-negron #copd #obituaries